Research Guidelines for Evaluating the Safety and Efficacy of Herbal Medicines
(1993; 94 pages)
Índice de contenido
Ver el documentoFOREWORD
Abrir esta carpeta y ver su contenido1. INTRODUCTION
Abrir esta carpeta y ver su contenido2. GENERAL CONSIDERATIONS IN HERBAL MEDICINE RESEARCH
Cerrar esta carpeta3. RESEARCH STUDIES
Ver el documentoLITERATURE BACKGROUND
Ver el documentoPROTOCOL PREPARATION
Ver el documentoQUALITY SPECIFICATIONS OF PLANT MATERIALS AND PREPARATION
Abrir esta carpeta y ver su contenidoNON-CLINICAL STUDIES
Cerrar esta carpetaCLINICAL TRIALS USING HERBAL MEDICINES
Ver el documentoCLINICAL TRIAL PROTOCOL DEVELOPMENT
Ver el documentoPHASES OF A CLINICAL TRIAL
Ver el documentoETHICS REVIEW BOARD
Ver el documentoRESPONSIBILITIES OF INVESTIGATORS
Ver el documentoRESPONSIBILITIES OF THE SPONSOR
Ver el documentoDATA MANAGEMENT
Ver el documentoSTATISTICAL ANALYSIS
Ver el documentoREPORTING
Ver el documentoEVALUATION OF HERBAL MEDICINE RESEARCH
Abrir esta carpeta y ver su contenidoTECHNOLOGY TRANSFER AND EDUCATION
Abrir esta carpeta y ver su contenido4. USING THE GUIDELINES
Abrir esta carpeta y ver su contenidoANNEXES
Ver el documentoNOTES
Ver el documentoBIBLIOGRAPHY
Ver el documentoSELECTED WHO PUBLICATIONS OF RELATED INTEREST
 

RESPONSIBILITIES OF THE SPONSOR

If the product under investigation is supplied by a manufacturer, or if the trial is undertaken at the request of a manufacturer, the manufacturer (sponsor) has obligations to maintain the integrity of the investigators, the protocol group and the ethics review board, and to prevent harm to a patient. The sponsor of a study can be an institution or an individual investigator as well as a manufacturer.

The material supplied for the trial will be prepared according to Good Manufacturing Practices (GMP) to ensure the quality of the material used in the investigation. All data on the product will be made available to the investigator before the trial design is completed.

The sponsor must meet all of the local requirements set by regulatory authorities and government agencies and should be aware of standards of good clinical practice.

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013